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Immune checkpoint inhibitors have advanced the treatment of melanoma. Nevertheless, a majority of patients are resis-
tant, or develop resistance, to immune checkpoint blockade, which may be related to prevailing immune suppression
by myeloid regulatory cells in the tumor microenvironment (TME). ORCA-010 is a novel oncolytic adenovirus that se-
lectively replicates in, and lyses, cancer cells. We previously showed that ORCA-010 can activate melanoma-exposed
conventional dendritic cells (cDCs). To study the effect of ORCA-010 on melanoma-conditioned macrophage devel-
opment, we used an in vitro co-culture model of human monocytes with melanoma cell lines. We observed a selective
survival and polarization of monocytes into M2-like macrophages (CD14+CD80-CD163+) in co-cultures with cell lines
that expressed macrophage colony-stimulating factor. Oncolysis of these melanoma cell lines, effected by ORCA-010,
activated the resulting macrophages and converted them to a more proinflammatory state, evidenced by higher levels
of PD-L1, CD80, and CD86 and an enhanced capacity to prime allogenic T cells and induce a type-1 T cell response. To
assess the effect of ORCA-010 on myeloid subset distribution and activation in vivo, ORCA-010 was intratumorally
injected and tested for T cell activation and recruitment in the human adenovirus nonpermissive B16-OVA mouse
melanoma model. While systemic PD-1 blockade in this model in itself did not modulate myeloid or T cell subset
distribution and activation, when it was preceded by i.t. injection of ORCA-010, this induced an increased rate and
activation state of CD8a+ cDC1, both in the TME and in the spleen. Observed increased rates of activated CD8+ T cells,
expressing CD69 and PD-1, were related to both increased CD8a+ cDC1 rates and M1/M2 shifts in tumor and spleen. In
conclusion, the myeloid modulatory properties of ORCA-010 in melanoma, resulting in recruitment and activation of
T cells, could enhance the antitumor efficacy of PD-1 blockade.
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INTRODUCTION
MELANOMA IS HIGHLY immunogenic, which explains its rel-
ative amenability to immunotherapy, but at the same time
calls for powerful immune escape to allow melanoma
tumors to grow and spread in the first place.1,2 As a
result, melanoma rapidly converts its tumor microen-
vironment (TME) into an immune suppressed state.
This multifactorial suppression can also result in pri-
mary or acquired resistance to immune checkpoint
blockade.3,4 Tumor-associated M2-like macrophages
(TAMs) are often the most abundant immune cell type
in the tumor milieu and may play a dominant role in
maintaining this immune suppressed and T cell-
excluded microenvironment.5–8
Like all macrophages, TAMs found at the tumor site
may develop either from recruited monocytes9 or are
tissue-resident macrophages and can acquire a phenotype
positioned anywhere along the continuous spectrum from
immune-suppressive M2 to T cell-stimulatory M1, de-
pending on environmental cues.10–13 In vivo, the release of
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macrophage-colony stimulating factor (M-CSF), TGF-b,
interleukin (IL)-6, and/or IL-10 by melanoma converts
monocytes into CD163+ M2-like macrophages.14–16 These
cells themselves release soluble factors that dampen
dendritic cell (DC) responses,17 and attract T regulatory
(Treg) cells.18 Through the release of IL-10, they ulti-
mately exclude CD8+ T cells from their surroundings,6,19
and support the tumor’s progression.20,21 On the opposite
end of the continuous polarization spectrum, M1-like
macrophages can release proinflammatory signals (IL-1b,
IL-12, and tumor necrosis factor alpha [TNF-a]) and pro-
mote a CD8+ T cell-mediated antitumor response through
antigen presentation and co-stimulation through CD80
and CD86.5,22,23
Oncolytic adenoviruses (OAdVs) have entered clinical
development and have shown favorable safety profiles;
they are now being investigated as adjuvant therapies,
alone or combined with chemotherapy or immunother-
apy for melanoma, pancreatic cancer, and glioma (as re-
cently reviewed24). Their role extends beyond simply
inducing oncolysis. By inducing immunogenic cell death
(ICD),25,26 danger-associated molecular patterns (DAMPs)
and (neo-)antigens are released into the TME.27–29 The
virus particles (VPs) themselves will also be taken up
by antigen-presenting cells (APC), and serve as pathogen-
associated molecular patterns (PAMPs), which are sensed
by TLRs and induce activation of the APC,30,31 although
adenoviruses can also induce APC activation in a TLR-
independent manner.32 Together, these OAdV-induced
triggers allow effective antitumor T cell responses to be
launched.28
The effect of OAdV on macrophages has been studied
in glioma mouse models,33,34 but has not been character-
ized for melanoma as far as we are aware. Using in vitro
culture models, we, in this study, show the effect of the
OAdVs ORCA-01035 on human monocyte-derived mac-
rophages in the face of melanoma-induced suppression
using an in-vitro co-culture model. We previously repor-
ted on the effects of ORCA-010 on the melanoma-
conditioned differentiation of monocytes to dendritic
cells (moDCs), in the presence of the moDC-inducing
cytokines IL-4 and granulocyte-macrophage colony-
stimulating factor (GM-CSF).36 Here, we studied the
effects of ORCA-010 on the unbiased melanoma-
conditioned differentiation of monocytes. While the im-
mature DCs and M2-like macrophages resulting from this
melanoma conditioning are both immune-suppressive
components of the TME, they are distinct cell popula-
tions with potentially different properties.
In addition, we have also studied the immune-
modulating effects of ORCA-010 in the B16-OVA mela-
noma mouse model. Our data show the oncolysis-
dependent activation of M2-like macrophages in human
monocyte/melanoma co-cultures, as well as the direct
proinflammatory effects of ORCA-010 in vivo. Based on
these results, ORCA-010, with its potent oncolytic activity
as well as local and systemic effects in vivo, could be an
attractive candidate for overcoming resistance to immune
checkpoint blockade in patients with melanoma.
MATERIALS AND METHODS
Cell lines
The human melanoma cell lines WM9, SK-MEL28, and
MEL-57 were described previously.36–40 Their identities
were confirmed by short tandem repeat analysis (Eurofins,
The Netherlands). The cell lines, including the B16-OVA
murine melanoma cell line, were maintained as described
previously,36,41 and were tested for mycoplasma.
Viruses
ORCA-010 (Ad5-D24-T1-RGD)35 is derived from
human adenovirus serotype 5 and carries the following ge-
netic modifications: the D24 mutation in the E1A region
providing cancer cell-selective replication, the T1 mutation
in the E3/19K gene that promotes oncolysis, and insertion of
an Arg-Gly-Asp (RGD) motif in the fiber knob that enhances
infection efficiency. The multiplicity of infection (MOI)
used in cultures was chosen to achieve 60% lysed melanoma
cells by day 6 of culture,36 that is, MOI 25-IU/cell for SK-
MEL28 and MEL57, and MOI 100-IU/cell for WM9.
Replication-deficient adenovirus serotype 5 with an RGD
motif and expressing luciferase under a CMV promoter
(Ad5-Luc-RGD)42 was used at MOI 100-IU/cell. The
OAdVs ONYX-01543 and Ad5-D24-RGD44 are condition-
ally replicative, and carry an E1B-55K deletion mutation, or
an E1A modification and RGD insertion, respectively.
Isolation of peripheral blood lymphocytes
and monocytes
Peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats from consenting healthy donors
(Sanquin Blood Supply Services, The Netherlands) and
from these, CD14+ monocytes were isolated by magnetic
bead separation, as previously described.36,45
Monocyte-derived macrophage polarization
Control macrophages (i.e., generated without melanoma
cell lines) were derived by culturing CD14+ monocytes in
complete RPMI medium (RPMI-1640 medium+Glutamine
& L-HEPES; ThermoFisher, Waltham, MA), with fetal
calf serum (10% FSC HyClone; GE, Boston, MA),
penicillin-streptomycin-glutamine (1% P/S/G; Thermo-
Fisher), and beta-2-mercaptoethanol (5.5 mM; Thermo-
Fisher) supplemented with 0.1 lg/mL M-CSF
(ImmunoTools, Germany), or GM-CSF (1,000 IU/mL;
ImmunoTools), to develop into resting M2-like and M1-
like macrophages, respectively.46 To activate the M2-like
macrophages, after 7 days of culture,47 a cocktail of re-
combinant human IL-4 (0.02 lg/mL rhIL-4; R&D Systems,














































Minneapolis, MN) and rhIL-10 (0.01 lg/mL; eBioscience,
ThermoFisher) was added. M1-like macrophages were
activated with lipopolysaccharide (0.1 lg/mL LPS;
Sigma Aldrich, St. Louis, MO) and interferon gamma
(1,000 IU/mL IFNc; R&D Systems) on day 7. Super-
natants were collected after 24 h (day 8), and phenotyping
was done by flow cytometry.
Melanoma cell lines were plated in 500 lL complete
RPMI medium. ORCA-010 was added 24 h later, 4 h be-
fore the addition of 2 · 10e5 CD14+ monocytes, in a 1:10
melanoma-to-monocyte ratio. ORCA-010 was added to
the melanoma cells 4 h before the monocytes were added,
to maximize virus uptake by the tumor cells. One hundred
microliters of supernatant was collected from the culture
on days 3, 7, and 8, and replaced by the same amount of
complete RPMI medium. Flow cytometry was performed
on day 8 (see Fig. 1A for timeline).
Alternatively, supernatants were collected from the
melanoma cell lines after 48 h of culture and run through a
0.22 lm Millex-GV Syringe Filter Unit (Merck KGaA,
Germany). The CD14+ monocytes were plated with 60%
tumor-derived supernatant (TDSN) and 40% complete
RPMI medium, and cultured for 8 days (Fig. 1B). Viability
was determined by flow cytometry with 7-amino-
actinomycin D (7-AAD) cell dye (Sigma, Ronkonkoma,
NY), and the cells were phenotyped or assessed for their T
cell priming capability as described below.
Mixed leukocyte reaction
On day 8 of the co-culture, the cells were harvested, and
the macrophages were separated from the tumor cells by
CD45 MACS according to the manufacturer’s protocol
(Miltenyi-Biotec, Germany). Purity (>90%) was checked
by flow cytometry. Peripheral blood lymphocytes (PBLs)
from healthy donor PBMCs depleted from monocytes by
CD14 MACS were labeled with intracellular fluorescent
dye 5,6-carboxyfluorescein diacetate succinimidyl ester
(3 lM CFSE; Sigma Aldrich). CFSE-labeled PBLs (10e5
cells per well) were cultured in a 96-well round-bottom
plate (Greiner Bio-One, Germany) in triplicate in a 10:1
ratio with macrophages (10,000 cells/well), in 200 lL
complete RPMI medium. Positive control for T cell stim-
ulation was CFSE-labeled PBLs stimulated at the start of
culture with phytohemagglutinin (5 lg/mL PHA; Oxoid).
The mixed leukocyte reaction (MLR) was cultured for
6 days, at which point, supernatants were collected and
flow cytometry was performed to assess proliferation.
Flow cytometry
Macrophage cultures were washed and fixed with
phosphate-buffered saline (PBS; Fresenius Kabi, The
Netherlands) supplemented with bovine serum albumin
(0.5 g BSA; ThermoFisher) and sodium azide (0.1%;
Sigma Aldrich), and stained with the following anti-
human antibodies: CD45 AF700 (clone HI30; Biolegend),
CD14 FITC (clone MFP9; BD Biosciences, San Diego,
CA), CD163 PE (clone GHI/61; Sony Biotechnology,
San Jose, CA), CD80 BV421 (clone 2D10; Biolegend),
CD86 PCP-Cy5.5 (clone 2331 [FUN-1]; BD Pharmingen),
PD-L1 APC (clone MIH1; eBioscience), and HLA-DR
FITC (clone L243; BD Pharmingen).
T cells and macrophages from an MLR culture were
fixed and stained with the following antibodies: CD14 PE-
CF594 (clone Mu-P9; BD Biosciences), CD3 BV421
(clone SK7; BD Horizon), CD4 AF700 (clone RPA-T4;
BD Pharmingen), and CD8 APC (clone SK-1; BD Bios-
ciences). Viability was determined with 7-AAD cell via-
bility dye (Sigma). The samples were acquired on a
Fortessa X20 flow cytometer (Becton-Dickinson, Franklin
Lakes, NJ), and analyzed with Kaluza Analysis software
1.3 (Beckman Coulter Life Sciences, Indianapolis, IN).
For phenotypic analysis of the mouse immune popu-
lations (described below), tumors and spleens harvested
on day 10 were processed into single-cell suspension and
fluorescently labeled with the anti-mouse antibodies listed
in Supplementary Table S1. The phenotypic definitions
of the myeloid populations are listed in Supplementary
Table S2, as described previously.48–55 Samples were
acquired on the Sony SH800 cytometer (Sony Bio-
technology), and analyzed with Kaluza analysis software
1.3 (Beckman Coulter Life Sciences).
To determine IFNc secretion by ovalbumin (OVA)-
reactive T cells, mouse splenocytes were thawed, passed
through a 100 lm cell strainer (BD), and restimulated
in vitro for 4–5 h with 1 lg/mL OVA-derived SIINFEKL
peptide56 (a kind gift of Prof. Yvette van Kooyk,
‰
Figure 1. Suppression by melanoma cell lines, and oncolysis by ORCA-010. The phenotype of monocyte-derived macrophages was determined by culturing
CD14+ monocytes (isolated from healthy donor PBMCs), with melanoma cell lines M57, WM9, and SK-MEL28 in vitro. (A) The co-culture and (B) TDSN culture
timelines, as detailed in the Materials and Methods. (C) Representative dot plots of CD45 and CD14 (top row), and the scatter properties of the CD14+CD45+
population (FSC and SSC; bottom row) for each co-culture and activated M2-like and M1-like macrophage controls. (D) Bar graphs with the percentage total
CD45+ cells (gray bars) in co-cultures with SK-MEL28, M57, and WM9, and the percentage of live CD45+ cells upon culture in supernatant derived from SK-
MEL28, M57, and WM9 (TDSN; white bars). (E) Representative histogram plots for the expression of CD163, PD-L1, CD80, CD86, and CD14 on macrophages in a
co-culture with M57, WM9, or SK-MEL28, compared to activated M2-like and M1-like control macrophages. The FMO control for each marker is delineated by
the marker in the histogram. The MFI of every marker is listed. (F) Incucyte live-cell images of CD14+ monocytes cultured with M-CSF (top) or GM-CSF (bottom),
compared to co-cultures with M57, WM9, or SK-MEL28 without ORCA-010 (medium; top row) or with ORCA-010 (bottom row). Magnification is 20 · . Distinct
macrophage morphology (black arrow), and cell debris (white arrow) are shown on the images. Data shown are mean – SEM for n = 3. Significant p-values by
paired t-test are shown. FMO, fluorescence minus one; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating
factor; MFI, mean fluorescent intensity; PBMCs, peripheral blood mononuclear cells; SEM, standard error of mean; TDSN, tumor-derived supernatant.




























































































Amsterdam UMC, The Netherlands) and 1:500 Golgi-
Plug protein transport inhibitor containing Brefeldin A
(BD Biosciences). After washing, cells were stained for
20 min in 1:5,000 fixable viability dye eFluor 506
(eBioscience, San Diego, CA) diluted in PBS to detect
dead cells, followed by an FccII- and FccIII-receptor
blocking step using the 2.4G2 antibody (BD Biosciences).
Following washing, the cells were stained with membrane
anti-mouse antibodies (CD3 and CD8, see Supplementary
Table S1). IFNc FITC (Supplementary Table S1) was in-
tracellularly stained in cells permeabilized with the
eBioscience FoxP3/Transcription Factor Staining Buf-
fer Set (ThermoFisher). Samples were acquired on the
Fortessa X20 flow cytometer (Becton-Dickinson) and ana-
lyzed on Kaluza Analysis Software v1.3 (Beckman Coulter,
Miami, FL).
Cytokine profiling
Supernatants collected from the in vitro cultures and
MLR were analyzed for IL-6, IL-8, IL-10, IL-1b, TNF-a,
and IL-12p70 using the human inflammatory cytometric
bead array (CBA) kit (BD Biosciences), and for IL-2, IL-4,
IL-6, IL-10, IFN-y, TNF-a, and IL17A using the human
Th1/Th2/Th17 CBA kit (BD Biosciences), respectively.
The samples were acquired on a Fortessa X20 flow cyt-
ometer (Becton-Dickinson), and analyzed with FCAP
Array 3 software (BD Biosciences).
In vivo experiment design and treatments
Four- to 6-week-old C57BL/6 JOlaHsd immune-
competent female mice (Envigo, Indianapolis, IN) were
quarantined for 1 week, and housed in a Biosafety level II
facility. All animal protocols were reviewed and approved
by the experimental animal committee of the University
of Helsinki (Finland) and the Provincial Government of
Southern Finland. Mice were engrafted subcutaneously with
0.25 · 106 B16-OVA cells in 100 lL RPMI-1640 medium in
the left flank. The tumor growth was monitored daily until
day 11 when tumors reached 3–4 mm in length. The mice
were randomly distributed into four groups (n = 4 per group),
namely PBS, ORCA-010, anti-PD-1, and ORCA-010 plus
anti-PD-1, and treatments were initiated (day 0).
Tumors received 1 · 109 ORCA-010 VP intratumorally
(i.t.) in saline mixed with filter-sterilized dimethyl sulf-
oxide (12% v/v DMSO; Sigma) on days 0, 1, 3, 6, and 9.
Groups treated with anti-mouse PD-1 InVivoMAb
(7.23 mg/mL, clone RMPI-14; BioXCell, Lebanon, NH)
were injected into the peritoneum (i.p.) on days 3, 6, and 9.
The vehicle control group received saline with filter-
sterilized DMSO i.t. and saline i.p. following the same
schedule as the groups receiving therapy. A prime-boost
treatment strategy was followed as described previously.41
Health was monitored daily, and tumor volume was
measured daily. Mice were anaesthetized with 2% iso-
flurane (Piramal Healthcare) for all treatments and tumor
measurements. Tumor volume was calculated as
0.5 · (shortest diameter)2 · longest diameter. To charac-
terize the effect of ORCA-010 and PD-1 blockade on the
immune response at the same time point, all mice were
sacrificed 10 days after treatments began, and the tumor
and spleen were collected, dissociated into single-cell
suspension, and frozen at -80C until further analysis.
Euthanasia was performed before the experimental end-
point if mice had an ulcer (open wound) at the injection
site, or if the tumor volume exceeded 18 mm. In the ve-
hicle control group, one mouse was found dead in the cage
on day 10, while in the combination group, one mouse was
sacrificed on day 9 due to an ulcer on the tumor.
Transcriptional analysis
CD163 (gene ID: 9332) and CSF-1 (M-CSF; gene ID:
1435) transcript levels from the publicly available dataset
‘‘Tumor Skin Cutaneous Melanoma TCGA’’ (TCGA-470-
rsem—tcgars; source ID: SKCM) were correlated using
R2 software (R2: Genomics Analysis and Visualization
Platform). This dataset was selected because of the high
sample number. No further distinctions based on disease
progression or metastasis were made.
Statistical analysis
All data were tested for significance with GraphPad
Prism version 8 (San Diego, CA). Student’s t-test was used
for significance testing of in vitro experiments. One-way
analysis of variance with Holm-Sidak’s multiple com-
parisons test was used to determine significance of the
in vivo mouse experiments. p-Values <0.05 were consid-
ered significant and are indicated in the graphs.
RESULTS
Melanoma-mediated survival and polarization
of M2-like macrophages
The effect of human melanoma cell lines on human
CD14+ monocytes was evaluated by both co-cultures with
the melanoma cells (Fig. 1A) or culture with cell line-
derived supernatants TDSN (Fig. 1B). In co-cultures
and cultures with TDSN, the M57 and WM9 cell lines
supported survival of CD45+CD14+ monocytes (which
acquired macrophage-like scatter properties), whereas
SK-MEL28 did not (Fig. 1C, D), demonstrating the pres-
ence of soluble melanoma-derived factors able to support
monocyte survival. In co-cultures, the monocytes skewed
to an M2-like phenotype (CD14+CD163+) with absent or
low expression levels of the B7-family members CD80,
CD86, and PD-L1 (Fig. 1E). With a round appearance,
morphologically, they resembled more M2- than M1-like
macrophages (Fig. 1F).
Of note, M-CSF- and GM-CSF-induced M2 and M1
monocyte-derived macrophages, activated by polarizing
cytokine cocktails, were included in phenotypic and
morphological assessments to denote two ends of the














































macrophage polarization spectrum. The onco-mutational
status of the tested cell lines and their secretion levels of
growth factors and cytokines were previously reported by
us.36 The three tested cell lines, in varying degrees, pro-
duced low levels of IL-10 and IL-6, but WM9 and M57
uniquely produced M-CSF, a potent growth and survival
factor for M2-like macrophages.11,16 The importance of
M-CSF in this regard was confirmed by a strong correla-
tion between the M2-related CD163 and M-CSF transcript
levels in a TCGA data set of n = 470 melanoma samples
(Supplementary Fig. S1). WM9, because of its metastatic
origin, its BRAF and PTEN mutation status,36 both related
to immune suppression and T cell exclusion,51,57 and its
ability to secrete M-CSF, was chosen as the model cell line
to further study the effects of ORCA-010-induced onco-
lysis in co-cultures with monocytes in vitro.
Oncolysis of melanoma cells by ORCA-010
activates macrophages, resulting in their
increased capacity to prime type-1 T cells
Infection of WM9 melanoma cells with ORCA-010
over the course of 4 h at an MOI of 100, before addition
of monocytes for a subsequent 8-day co-culture (Fig. 1A),
did not prevent expression of the M2-associated markers
CD14 and CD163 on the melanoma-conditioned macro-
phages (Fig. 2A, B), but it did lead to their increased
forward and side scatter properties consistent with a more
M1-like morphology (Fig. 2A). This was confirmed by sig-
nificant upregulation of CD80, CD86, and PD-L1, similar
to the expression profile of M1-macrophages (Fig. 2B, C).
Of note, polychromatic staining showed that although
CD80, CD86, and PD-L1 were upregulated by ORCA-
010, CD163 was not downregulated on the same CD14+
cells: as such, macrophage activation was observed, rather
than classic M2-to-M1 skewing.
Similar observations for CD86 were made for the M57,
and to a lesser extent, SK-MEL-28 cell lines (data not
shown). A comparison with nonreplicative adenovirus
(Ad5-Luc-RGD) showed this activation to be specific to the
OAdV ORCA-010 (Fig. 2D), and was therefore, in this
model, more likely related to DAMPs, released upon
ORCA-010-induced oncolysis (Fig. 1F), than to adenovirus-
derived PAMPs. Indeed, Ad5-D24-RGD, which, similar to
ORCA-010, was able to induce oncolysis in WM9 mela-
noma cells, also induced upregulation of the B7 family
members CD80, CD86, and PD-L1 on monocyte-derived
macrophages, whereas ONYX-015, an adenovirus with at-
tenuated oncolytic potential in comparison to D24-type
viruses, which did not induce detectable oncolysis in WM9
melanoma cells, did not (Supplementary Fig. S2). Im-
portantly, macrophages isolated from ORCA-010-infected
WM9 co-cultures displayed a significantly improved ability
over macrophages differentiated in untreated WM9 co-
cultures to prime and activate both CD4+ and CD8+ T cells
in a 6-day allogeneic MLR (Fig. 3A–C). These primed T
cells generally secreted higher levels of the type-1 cytokines
IFNc, IL-2, and TNF-a (Fig. 3D). Significantly higher
IFNc:IL-10 and IFNc:IL-4 (ns) ratios indeed confirmed
type-1 effector T cell skewing.
Intratumoral delivery of ORCA-010 combined
with systemic PD-1 blockade promotes
a systemic inflammatory response
and increased CD8+ T cell infiltration
To assess the effects of ORCA-010 on the recruit-
ment and activation of myeloid subsets and T cells in vivo,
B16-OVA bearing syngeneic BL6 mice were treated in-
tratumorally with ORCA-010, followed by systemic anti-
PD-1 administration41 (Fig. 4A). At the time of sacrifice
(day 10), the mean tumor volume was the same for all
groups (Fig. 4B), consistent with the fact that murine tu-
mors are not permissive to OAdV replication and therefore
will not undergo oncolysis. Myeloid and T cell subsets
were assessed by flow cytometry in both tumors and
spleens.
In the tumor, no differences in frequencies of myeloid-
derived suppressor cells (MDSC, data not shown) or
TAMs were observed, nor any treatment-related shifts in
M1-M2 phenotypes; rather, a significant increase was
observed in CD8a+ conventional dendritic cell 1 (cDC1)
upon combined ORCA-010 administration and PD-1
blockade (Fig. 4C). Combined ORCA-010 and PD-1
treatment also increased rates of tumor-infiltrating CD8+
T cells in an activated state as evidenced by their increased
CD69 expression (Fig. 4D). Numbers of CD8+-infiltrating T
cells were strongly correlated to tumor-associated CD8a+
cDC1, both of which were recruited upon i.t. ORCA-010
delivery (Fig. 4E, left panel). PD-1 expression levels on
‰
Figure 2. Oncolysis by ORCA-010 induces activated macrophages in a co-culture with WM9 melanoma cell line. After 8 days of co-culture with the WM9
melanoma cell line, the phenotype of the CD45+ monocyte population was determined by flow cytometry. (A) Representative dot plots of the CD45+CD14+
population (top row) and the scatter properties within that gate (FSC, SSC; bottom row) for WM9 co-culture without (‘‘medium’’) or with ORCA-010 (‘‘+ORCA-
010’’), compared to activated M2-like and M1-like control macrophages. (B) Representative dot plots for the co-expression of markers on CD45+ macrophages
in WM9 co-culture without (‘‘medium’’; left panel) or with ORCA-010 (right panel). Activated M2-like and M1-like macrophages are included as controls. Gates
were set on FMO controls. (C) The corresponding bar graphs of the dot plots in (B), with the percentage of marker co-expression on macrophages from WM9
co-culture without ‘‘medium’’ (light gray) or with ORCA-010 (dark gray) (n = 5, mean – SEM). (D) Macrophages from a WM9 co-culture infected with a
replication-deficient adenovirus vector (Ad5-Luc-RGD) or with ORCA-010 were phenotyped on day 8 of co-culture by flow cytometry. The MFI of macrophage-
associated markers HLA-DR, CD80, CD86, and PD-L1 are shown for WM9 co-culture with Ad5-Luc-RGD (light gray) or ORCA-010 (dark gray), relative to the
expression on macrophages from an uninfected WM9 co-culture (shown by a solid line at y = 1). Data are mean – SEM for n = 3. Significant p-values of paired
t-test are shown.




























































































Figure 3. Activated macrophages from a WM9 co-culture with ORCA-010 can expand T cells in an allogeneic MLR and induce the secretion of Th1 cytokines.
After 8 days, macrophages were sorted from co-cultures with melanoma cells based on CD45, and were subsequently cultured in a 1:10 target-to-effector ratio
with CFSE-labeled, non-HLA-matched T cells for 6 days, upon which T cell proliferation was assessed by flow cytometry. Cytokines were quantified in 6-day
MLR supernatants. (A) The scatter properties (FSC and SSC) of lymphocytes cultured with macrophages from WM9 co-culture alone (‘‘medium’’), or with
ORCA-010, compared to control T cells cultured with PHA, gated on viable CD3+ cells. (B) For each MLR condition, the dot plots illustrate the proliferation (CFSE
signal) of CD4+ (top row) and CD8+ (bottom row) T cells. (C) The percentage proliferated (CFSElo) CD4 and CD8 T cells (n = 4; mean – SEM). (D) Cytokine
concentrations (pg/mL) of IFNc, TNF-a, IL-2, IL-10, IL-4, and IL-6 and (E) IFNc:IL-10 and IFNc:IL-4 ratios on day 6 of MLR (n = 3; mean – SEM). The dotted line in
bar graphs shows the lower limit of detection. Statistical significance (paired t-test) is indicated as p-values. IFNc, interferon gamma; IL, interleukin; MLR,















































tumor-infiltrating CD8+ T cells, a sign of tumor specifici-
ty,58,59 were related to both activation of CD8a+ cDC1 and
M1-like macrophage content (Fig. 4E, right panels).
In the spleen, M2-like macrophages decreased, and
CD11c+ cDC and CD8a+ cDC1 increased in response to
ORCA-010 and anti-PD-1 combination treatment
(Fig. 5A). This was accompanied by increases in both
CD8+ and CD4+ T cells in a combination treatment-
induced activation state, as evidenced by increases in PD-1
expression rates (Fig. 5B). Upon in vitro restimulation
of splenocytes with the immunodominant OVA-derived
epitope SIINFEKL, low-frequency OVA-reactive CD8+ T
cells producing IFNc were measurable by day 10 after
intratumoral delivery, confirming the priming of tumor-
Figure 4. ORCA-010 and anti-PD-1 combination therapy induces T cell infiltration and activation in B16-OVA melanoma tumors. (A) The treatment schedule in
C57BL/6 mice. PBS and ORCA-010 were injected intratumorally (i.t.), and anti-PD-1 was administered systemically (i.p.) (n = 4 per group). (B) The fold change in
tumor volume (mm3) on the day of sacrifice. (C) The percentage of TAMs, M2-like and M1-like macrophages, cDCs, CD8a+ cDCs, and (D) CD8+ T cells and
CD69+CD8+ T cells are shown. Significance by one-way ANOVA is indicated as p-values for n = 3–4 mice per group. Note: In the vehicle control group, one
mouse was found dead in the cage on day 10, while in the combination group, one mouse was sacrificed on day 9 due to an ulcer on the tumor. (E) Correlation
between CD8+ T cells and CD8a+ DCs (left panel), PD-1 MFI on CD8+ T cells and activated CD8a+ DCs (middle panel), and PD-1 MFI on CD8+ T cells and M1-like
macrophages (right panel) in the tumor. Linear regression was used to calculate the correlation coefficient (R2) and p-value. ANOVA, analysis of variance; cDC,
conventional dendritic cell; OVA, ovalbumin; PBS, phosphate-buffered saline; TAM, tumor-associated M2-like macrophage.














































specific T cells (Fig. 5C). CD8+ T cell rates in the
spleen, like in the tumor, were correlated to CD8a+ cDC1
frequencies; the reduction in M2-like macrophages in
combination-treated mice correlated with an increase
in CD4+ T cell frequencies and PD-1 expression rates in
CD8+ and CD4+CD69+ T cells (Fig. 5D).
DISCUSSION
For patients with melanoma, combined immune check-
point blockade with nivolumab (anti-PD-1) and ipilimu-
mab (anti-CTLA-4) has improved the 5-year overall
survival rate to levels exceeding 50%.2 Despite this
spectacular result, almost half of the patients either fail
to respond or develop resistance to treatment. Oncolytic
viruses are promising novel therapeutic agents that may
help overcome this primary or acquired resistance. They
can achieve in vivo immunization against cancer, through
inducing the release of tumor (neo-)antigens in an im-
munogenic manner, while transforming the TME into a
T cell-inflamed state.5,7,60 Indeed, Ribas et al. clearly
demonstrated this principle in patients with advanced
melanoma, who received i.t. injections of the oncolytic
virus T-VEC (a herpes simplex virus encoding GM-CSF),
which, combined with PD-1 blockade, dramatically in-
creased T cell infiltration, not only of injected but also of
noninjected lesions.61
Myeloid subsets have been recognized as holding the
key to ensuring both efficient antitumor T cell priming and
attracting effector T cells to the TME. It is therefore vital
that oncolytic viruses ensure proper APC development
and activation, even in the face of melanoma-associated
immune suppression. In our in vitro culture model, we
found that melanoma cell lines, without exogenously
added cytokines, polarized monocytes into CD163+ M2-
like macrophages, lacking expression of co-stimulatory
markers. Soluble factors implicated in skewing monocytes
to M2-like macrophages are M-CSF, IL-6, and IL-10, and
are dependent on cross-talk in the TME.62–65 In our WM9-
Figure 5. Rates and activation state of immune cell subsets in the spleen of ORCA-010 and anti-PD-1-treated B16-OVA tumor-bearing mice. Phenotypic analysis
of cells in the spleen of mice, 10 days after the start of treatment. (A) Percentage of macrophages, M2-like and M1-like macrophages, CD11c+ cDCs, CD8a+
cDCs, and (B) CD8+ T cells, CD4+ T cells, PD-1+CD8+, and PD-1+CD4+CD69+ T cells. (C) The percentage of CD8+IFNc+ T cells following in vitro restimulation of
splenocytes with OVA-specific SIINFEKL peptide. (D) Correlation, from left-to-right, between CD8+ T cells and CD8a+ cDCs, and CD4+, PD-1+CD8+, and PD-
1+CD4+CD69+ T cells with M2-like macrophages, respectively. Note: In the vehicle control group, one mouse was found dead in the cage on day 10, while in the
combination group, one mouse was sacrificed on day 9 due to an ulcer on the tumor. Data are mean – SEM for n = 3–4 mice per group; significant p-values are
indicated (one-way ANOVA). Linear regression was used to calculate the correlation coefficient (R2) and p-value, indicated on each panel in (D).














































based model, M-CSF was the most likely culprit in this
context. Of note, macrophages can acquire a composite
M1/M2 phenotype on the continuous M1-M2 polarization
spectrum4 in response to various cues in their milieu.11,22
Although macrophages in WM9 co-cultures did not
downregulate CD14 or CD163 upon ORCA-010 infection
of the melanoma cells, these macrophages did increase
their expression of B7-family ligands (CD80, CD86, and
PD-L1), activation markers that are commonly expressed
by M1-like macrophages upon interferon- and TLR-
mediated signaling.66 Inflammatory cytokines secreted in
the WM9 co-cultures measured on day 8 were not mod-
ulated by ORCA-010, which might have been related to
consumption of released cytokines in the cultures (Sup-
plementary Fig. S3), and the maintained expression
of CD163 on the macrophages could be by continuous
M-CSF stimulation in a closed co-culture system,21,67 or
by TLR-mediated activation of monocytes.67,68
Eriksson et al.69 demonstrated that CD40L-armed Ad5/
35 could lower rates of CD11b+CD163+ M2-like cells
after 5 days of co-culture with human monocytes. How-
ever, this was mostly due to the CD40L transgene as, in
accordance with our findings, this shift was not observed
with the unarmed Ad5/35. It was also the CD40L trans-
gene that induced subsequent IL-12 release by the acti-
vated monocyte-derived macrophages. Similarly, in an
in vivo pancreatic tumor model, the unarmed Ad5/35 on-
colytic virus did not impact the M1/M2 ratio, but rather the
murine CD40L-expressing virus induced M1-like macro-
phages.69 As Ad5-Luc-RGD per se could not induce this
activation, it is most likely that DAMPs, released upon
ORCA-010-induced oncolysis, were responsible. Indeed,
Heinio et al.70 demonstrated that infection of SK-MEL28
with an OAdV resulted in the release of DAMPs (such as
ATP) that activated moDCs.26,71 This is in keeping with
our own previous observation that oncolysis induced by
ORCA-010 was responsible for the activation of
melanoma-conditioned moDCs rather than PAMPs derived
from the virus itself.36
Strikingly, both in melanoma/monocyte co-cultures
without differentiation-inducing cytokines presented
herein and in co-cultures with DC differentiation-inducing
cytokines,36 the resulting APCs acquired a CD14+CD163+
M2-like phenotype, which ORCA-010 infection was un-
able to steer toward M1-like macrophage or CD1a+ moDC
differentiation, respectively. However, in both instances, it
did induce activation that resulted in an ability of the
generated APCs to prime a type-1 T cell response.
In the B16-OVA mouse model, we investigated the im-
mune response to combination therapy of ORCA-010 with
PD-1 blockade. ORCA-010, like all OAdV, cannot replicate
in murine B16-OVA tumors,72 but it can infect B16-OVA
cells.73 The resulting antiviral immune response can prime
antitumor immunity through epitope spreading, and promote
the homing of immune effector cells into tumors through the
expression of CCL5 and CXCL10.74–76 The in vivo
myeloid-activating effects of ORCA-010 observed in the
B16-OVA model may derive from a combination of T cell-
induced death of virus-infected tumor cells, leading to the
release of activating DAMPs, and direct binding/uptake of
the virus, carrying PAMPs, by myeloid cells.77–79 Both
TLR-dependent and TLR-independent signaling are acti-
vated in macrophages that phagocytose tumor cell debris
and VP.32 The intracellular sensing of dsDNA of ORCA-
010 can also trigger IRF3 and NF-kB transcription factors,
activating type-I interferon signaling and proinflammatory
cytokine expression (IL-1b and TNF-a).31,77,80 Consistent
with this, i.t. delivery of ORCA-010 facilitated the recruit-
ment of cross-presenting CD8a+ DCs (cDC1 like) and CD8+
T cells to the TME, both known to enable efficacious PD-1
blockade.51
Indeed, in concert with PD-1 blockade, CD69+CD8+ T
cell frequencies increased in the tumor. These could po-
tentially develop into tissue-resident memory T cells.81–83
Functionally, CD69+CD8+ T cells can secrete IFNc,84
induced by the action of anti-PD-1.74 Likely, as previously
described by Spranger et al.,51 recruited cDC1 were re-
sponsible for CXCL10 expression, which would subse-
quently have attracted CD8+ T cells to the TME. This is
supported by the observed perfect correlation between
frequencies of both subsets in the tumor. Although we did
not observe a reduction of M2-like macrophages at the
tumor, we showed that M1-like macrophages correlated
with PD-1 expression on CD8+ T cells. The failure to
demonstrate macrophage modulation by ORCA-010 in the
TME may have been due to its inability to induce onco-
lysis in the mouse model.
Interestingly, we did observe increased M1-like macro-
phage content in the spleen upon combined ORCA-010 and
anti-PD-1 treatment and striking inverse correlations be-
tween M2 rates and frequencies of activated CD8+ and
CD4+ T cells in the spleen, expressing PD-1, and CD69 and
PD-1, respectively. Combination treatment also increased
CD8a+ cDC1 rates in the spleen, which correlated with
CD8+ T cell frequencies. For now, it remains unclear how i.t.
injections of ORCA-010 led to these systemic myeloid
subset-modulating effects, but conceivably, adenovirus-
induced type-1 IFNs may have been responsible.85,86
CONCLUSION
To conclude, ICD of melanoma cells by ORCA-010
activates human macrophages in vitro, functionally
equipping them to prime and drive a type-1 T cell re-
sponse. In the B16-OVA melanoma model, i.t. ORCA-010
injection combined with systemic PD-1 blockade mobi-
lized and recruited cDC1 and attracted activated effector
T cells to the TME. Interestingly, ORCA-010 and anti-
PD-1 combination treatment induced an M2-like macro-
phage reduction in the spleen, which was accompanied by














































increased systemic frequencies of activated CD4+ and
CD8+ T cells, expressing PD-1. Altogether, these data
clearly support the intratumoral delivery of ORCA-010 to
enhance PD-1 blockade efficacy in melanoma.
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